Proceedings of the International scientific and practical conference ―Science at the Frontier of Civilizations: Challenges and Perspectives‖ (December 27-29, 2025) / Publisher website: www.naukainfo.com. – Helsinki, Finland, 2026. – 252 p.

112 практику визначення імуногістохімічних маркерів у всіх морфологічних підтипах РЯ. СПИСОК ВИКОРИСТАНИХ ДЖЕРЕЛ: 1. Ledermann JA, Matias-Guiu X, Amant F, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol . 2024;35(3):248- 266. doi:10.1016/j.annonc.2023.11.015 2. Bates M, Mohamed BM, Lewis F, et al. Biomarkers in high grade serous ovarian cancer. Biochim Biophys Acta Rev Cancer . 2024;1879(6):189224. doi:10.1016/j.bbcan.2024.189224 3. Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol . 2018;80:11-27. doi:10.1016/j.humpath.2018.06.018 4. Chui, M.H.; Momeni Boroujeni, A.; Mandelker, D., et al. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: Rare exceptions to the binary classification of ovarian serous carcinoma. Mod. Pathol. 2021 , 34 , 490–501. https://doi.org/10.1038/s41379-020-00648-y 5. Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel) . 2022;14(2):416. Published 2022 Jan 14. doi:10.3390/cancers14020416 6. González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol . 2023;34(10):833-848. doi:10.1016/j.annonc.2023.07.011 7. Duchon M, Naik R, Lecuru F, et al. Management of Recurrence in Ovarian Cancer-The Role of Surgery and HIPEC with Relevance to BRCA Testing in a PARPi Landscape. Cancers (Basel). 2025;17(4):646. doi:10.3390/cancers17040646